# Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Source: https://onco.cc/trials/nct06767813/  
OnCo record `nct06767813` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine and Anlotinib in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.

## Summary

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms is a phase 2 interventional study registered as NCT06767813 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 80 participants planned, started 2024-03-19 and due to reach its primary completion in 2026-11. Interventions recorded: TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection and Anlotinib capsules.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06767813
- Phase: 2
- Setting: Multi-cohort, Open, Phase II Clinical Study of TQB2868 Injection Combined With Arotinib Capsule and Chemotherapy in the First-line Treatment of Pancreatic Neoplasms
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06767813: https://clinicaltrials.gov/study/NCT06767813

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [TQB2868](https://onco.cc/drugs/tqb2868/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06767813.json